[ad_1]
Anvisa (National Health Surveillance Agency) granted the certification of good manufacturing practices to WuXi Biologics, responsible for the manufacture of the active biological pharmaceutical ingredient of the vaccine developed by AstraZeneca in partnership with the University of Oxford and the Oswaldo Cruz Foundation.
The Ministry of Health has a partnership with the company to produce the immunizer.
The complete stage is one of the prerequisites for the continuity of the vaccination registration process. The information was released on Wednesday night (23) by the federal government.
According to the government, after an inspection carried out from December 7 to 11, Anvisa’s technical team concluded on Wednesday the technical evaluation of the complementary information sent by the company.
This week, Anvisa had already granted the certificate of good practices to Sinovac, the Chinese company responsible for Coronavac and a partner of the Butantan Institute, in São Paulo.
Coronavac is the bet of the governor of São Paulo, João Doria (PSDB), to supply the Covid-19 vaccine to the population of São Paulo and has been at the center of a dispute with President Jair Bolsonaro (no party).
Bolsonaro openly works against the immunization campaign and has already said that the federal government would not buy vaccines from China because it would not bring security.
However, the manufacturer WuXi Biologics, which has just received certification from the Bolsonaro government, is also located in China.
This Wednesday a resolution with the certification was published in the Official Gazette in an extra edition. The law can anticipate, according to the government, in about 10 days the initial forecast of publication of the certification decision.
In addition to being one of the prerequisites for the continuity of the vaccine registration, it is also necessary for an eventual request for authorization for emergency use that can be submitted to the regulatory agency. The certification is valid for two years.
